Last reviewed · How we verify
Sonazoid™
Sonazoid is a liver-specific contrast agent that enhances the visibility of liver lesions during MRI.
Sonazoid is a liver-specific contrast agent that enhances the visibility of liver lesions during MRI. Used for Liver cancer diagnosis and monitoring, Liver lesion detection.
At a glance
| Generic name | Sonazoid™ |
|---|---|
| Also known as | perfluorobutane, NC100100, Perfluorobutane, Contrast ultrasound microvascular perfusion imaging |
| Sponsor | GE Healthcare |
| Drug class | Contrast agent |
| Modality | Small molecule |
| Therapeutic area | Radiology |
| Phase | Phase 3 |
Mechanism of action
It works by accumulating in liver cells and causing them to produce a signal that can be detected by MRI, allowing for better visualization of liver lesions. This is particularly useful for diagnosing and monitoring liver cancer and other liver conditions.
Approved indications
- Liver cancer diagnosis and monitoring
- Liver lesion detection
Common side effects
- Nausea
- Allergic reactions
- Kidney problems
Key clinical trials
- Phase 4 Paediatric Study to Evaluate Sonazoid Safety and Efficacy for Contrast-Enhanced Ultrasound Liver Imaging (PHASE4)
- An Efficacy and Safety Study of Sonazoid™ and SonoVue® in Participants With Focal Liver Lesions, Undergoing Pre- and Post-Contrast Ultrasound Imaging (PHASE3)
- A Study to Evaluate Pharmacokinetics of Sonazoid™ Following Intravenous Bolus Injection in Healthy Volunteers (PHASE1)
- Sonazoid Enhanced Liver Cancer Trial for Early Detection (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sonazoid™ CI brief — competitive landscape report
- Sonazoid™ updates RSS · CI watch RSS
- GE Healthcare portfolio CI